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012.05.0Abstract Background: Atrial ﬁbrillation (AF) is the most common type of arrhythmia and recog-
nized as a risk factor for thromboembolism. Endothelial damage or dysfunction may contribute to
increase the risk of thromboembolism via the mediation of a prothrombotic or hypercoagulable
state.
Objectives: The aim of the current study is to investigate endothelial dysfunction (represented by
brachial ﬂow-mediated dilatation ‘‘FMD’’) and inﬂammation (represented by hs-CRP) in patients
with paroxysmal atrial ﬁbrillation.
Subjects and methods: Forty-two patients with AF taken from the Cardiology Department and
Outpatients Clinic, Specialized Medical Hospital, Mansoura University, in the period between
February 2011 and May 2011 were enrolled in our study, the patients were then subsequently
divided according to the clinical type of AF into Group I: comprised 20 patients with paroxysmal
AF (PAF) with mean age 57.35y. Group II: comprised 22 patients with chronic AF (CAF) with
mean age 57.68y. Twenty control subjects without AF were enrolled in this study (Group III).
Patients and control groups were subjected to clinical evaluation, electrocardiography (ECG), echo-
cardiography and brachial FMD (using external brachial ultrasonography. Serum level of hs-CRP
was assessed in all subjects. The diameter change induced by FMD was expressed as the percent
change relative to that at the initial scan (FMD%) according to the following equation:
FMD% ¼Maximum diameter baseline diameter
Baseline diameter
 100:
Results: Left atrial diameter was signiﬁcantly increased when compared either GI or GII with
control group (3.96 ± 0.27; 4.7 ± 0.48 vs 3.05 ± 0.35 cm) (P< 0.001). Brachial ﬂow-mediated dila-
tation difference and percentage change of FMD were signiﬁcantly lower in groups I and II in com-
parison to group III (0.09 ± 0.05; 0.09 ± 0.04 vs 0.79 ± 0.07 mm) and (1.96 ± 0.98; 1.99 ± 0.89 vs2393 7098.
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212 A.A. Wafa et al.18.3 ± 3.26) (P< 0.001). High sensitive CRP was signiﬁcantly higher when compared either group
I or group II with control group. Also hs-CRP has signiﬁcantly increased when compared GII with
group I (8.35 ± 1.55; 10.58 ± 1.75 vs 3.61 ± 0.61 mg/L) (P< 0.001).
Conclusion: Patients with PAF are comparable in the degree of endothelial dysfunction (reﬂected as
impaired brachial artery FMD) and inﬂammatory element (reﬂected as a higher serum hs-CRP) to
CAF. This may explain why the risk of thromboembolism in PAF is comparable with that in
CAF patients.
ª 2012 Egyptian Society of Cardiology. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Atrial ﬁbrillation (AF) is the most common type of arrhythmia
and recognized as a risk factor for thromboembolism, but the
pathogenesis of thrombus formation remains unclear. Previous
reports have suggested that loss of atrial contraction in AF is
associated with thrombogenesis.
The risk of ischemic stroke increases by three- to fourfold in
patients with non-valvular AF1 and anticoagulant therapy
reduces this risk by two-thirds.2
In patients with chronic AF there is an increased activation
of platelets and the coagulation system in peripheral venous
blood.3–6. In the patients with paroxysmal AF, atrial ﬁbrilla-
tion itself enhances platelet aggregation and coagulation and
these processes are inﬂuenced by the duration of AF.7
Interestingly, however, ischemic stroke occurs in the pa-
tients with paroxysmal AF even during sinus rhythm.8
Endothelial damage or dysfunctionmay contribute to the in-
creased risk of thromboembolism via the mediation of a
prothrombotic or hypercoagulable state. However, the precise
pathophysiological mechanism(s) relating endothelial dysfunc-
tion toAF and thromboembolism are yet to be fully elucidated.9
C-reactive protein (CRP), a sensitive marker of inﬂamma-
tion, is known to be associated with vascular dysfunction.10
Endothelial dysfunction is one of the initial pathological
processes of atherosclerosis and has been associated with in-
creased cardiovascular risk. Brachial artery ﬂow-mediated
dilatation (FMD) is a validated non-invasive physiological
measure widely used as a research method to quantify endo-
thelial function. Brachial FMD has been shown to be an inde-
pendent predictor of cardiovascular outcomes.11
The dilatation response with increased blood ﬂow is mainly
mediated by nitric oxide released from arterial endothelial
cells.12
2. Objectives
The aim of the current study is to investigate endothelial dys-
function (represented by brachial FMD) and inﬂammation
(represented by hs-CRP) in patients with paroxysmal atrial
ﬁbrillation.
3. Subjects and methods
Fifty selected patients with AF were taken from the Cardiol-
ogy Department and Outpatients Clinic, Specialized Medical
Hospital, Mansoura University, Egypt, in period between
February 2011 and May 2011 and enrolled in our study, the
patients were then subsequently divided according to the
clinical type of AF into Group I: comprised 22 patients withparoxysmal AF (PAF) with mean age 57.35y (two patients
did not agree to go for the study protocol). Group II: com-
prised 28 patients with chronic AF (CAF) with mean age
57.68y (six patients did not agree to go for the study protocol).
Twenty control subjects without AF were enrolled in this study
(Group III).
The study was approved by the Ethics Committee of
Mansoura Faculty of Medicine and all patients gave the writ-
ten informed consent to participate in the study.
The patients with valvular heart disease, hyperthyroidism,
diabetes mellitus, malignancy and hepatic or renal impairment
were excluded from our study. We also exclude the patients
with acute cardiovascular or cerebrovascular events.
In patients with chronic AF we did not exclude patients
with hypertension or chronic stable angina.
Hypertension was considered when systolic blood pressure
over 140 mmHg and/or diastolic blood pressure over 90 mmHg,
and/or taking antihypertensive.
Dyslipidemia was deﬁned as total cholesterol over 220 mg/
dL and/or current treatment with statins.
4. Clinical evaluation
Complete history and physical examination were done for all
patients and control subjects. Past electrocardiography trac-
ings were reviewed. Paroxysmal AF was deﬁned when no more
than two consecutive ECGs of AF and conﬁrmed intercession
by documented sinus rhythm.
Chronic AF was deﬁned as AF documented electrocardio-
graphically on at least two occasions at least 2 months apart.
5. Echocardiographic measurements
M-mode, 2D and Doppler transthoracic echocardiography
were performed for patients and control subjects. LA and
LV dimensions and LV fractional shortening were measured
by M-mode echocardiography.6. Endothelial measurements
The subjects were kept in the supine position in a quiet, dark,
and air-conditioned room (with a constant temperature of
23–26 C throughout the study). After 20 min of rest, the basal
brachial artery diameter was measured. Endothelium-depen-
dent and endothelium-independent vasodilatations were exam-
ined in the brachial artery using external ultrasound.
Measurement was done by the same operator.
The right brachial artery was scanned in the longitudinal
section 3–5 cm above the antecubital fossa using a high-resolu-
Table 1 Clinical characteristics and medications of study groups.
GI (PAF) (n= 20) GII (CAF) (n= 22) GIII (control) (n= 20) P value
Age 57.35 ± 3.9 57.7 ± 3.5 57.8 ± 2.6 0.912
Male (n, %) 13 (65%) 14 (63.6%) 13 (65%) 0.994
Hypertension 9 (45%) 10 (45.5%) 8 (40%) 0.927
Smoking 3 (15%) 4 (18.2%) 2 (10%) 0.752
Dyslipidemia 7 (35%) 7 (31.8%) 7 (35%) 0.968
Medications
Aspirin 2 (10%) 3 (13.6%) 0 (0%) 0.249
Beta blockers 6 (30%) 6 (27.3%) 2 (10%) 0.257
ACF-I/ARBs 9 (45%) 9 (40.9%) 8 (40%) 0.943
CCB 7 (35%) 7 (31.8%) 6 (30%) 0.943
Warfarin 15 (75%) 19 (86.4%) 0 (0%) <0.001
Antiarrhythmics 9 (45%) 7 (31.8%) 0 (0%) <0.001
Statins 4 (20%) 5 (22.7%) 0 (0%) 0.079
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ear-array transducer. Forearm blood ﬂow was altered by
inﬂating the blood pressure tourniquet placed around the fore-
arm. The cuff was inﬂated to 20 mmHg higher than the systolic
blood pressure for 5 min. Endothelium-dependent FMD was
assessed as the percent change in the arterial diameter in re-
sponse to reactive hyperemia associated with 5 min of
ischemia.
The diameter change induced by FMD was expressed as the
percent change relative to that at the initial scan (FMD%)
according to the following equation 11:
FMD% ¼Maximum diameter baseline diameter
Baseline diameter
 1007. Laboratory measurements
All patients and control subjects were subjected to:Table 2 Echocardiographic data of study groups.
GI (PAF) (n= 20) GII (CAF) (n=
ESD 2.94 ± 0.34 3.04 ± 0.38
EDD 4.63 ± 0.41 4.7 ± 0.38
IVST 1.21 ± 0.18 1.29 ± 0.21
PWT 1.14 ± 0.15 1.16 ± 0.17
FS% 34.25 ± 1.89 34.64 ± 2.3
LAD 3.96 ± 0.27 4.7 ± 0.48
ESD= end systolic diameter, EDD= end diastolic diameter, IVST =
FS%= fractional shortening, LAD= left atrial diameter.
P1: GI vs GII (PAF vs CAF), P2: GI vs GIII (PAF vs control), P3: GII– Routine laboratory proﬁle: including fasting and 2 h post
prandial blood sugar.
– Fasting serum lipid proﬁle: using enzymatic colorimetric
methods (Human, Wiesbaden, Germany).
– Estimation of serum level of hs-CRP using ELISA tech-
nique (Diasys Lab Inc., Webster, USA).
8. Statistical analysis
Data were analyzed using SPSS (Statistical Package for Social
Sciences) version 15. Qualitative data were presented as num-
ber and percent. Comparison between groups was done by
Chi-square test. Quantitative data were tested for normality
by Kolmogrov–Smirnov test. Normally distributed data were
presented as mean ± SD. Student t-test was used to compare
between two groups. F-test (one way Anova) was used to com-
pare between more than two groups. Pearson’s correlation22) GIII (control) (n= 20) P value
2.86 ± 0.24 P1 = 0.373
P2 = 0.399
P3 = 0.07
4.45 ± 0.39 P1 = 0.568
P2 = 0.159
P3 = 0.04
1.20 ± 0.17 P1 = 0.192
P2 = 0.929
P3 = 0.152
1.15 ± 0.16 P1 = 0.706
P2 = 0.843
P3 = 0.861
36.95 ± 2.5 P1 = 0.558
P2 < 0.001
P3 = 0.003
3.05 ± 0.35 P1 < 0.001
P2 < 0.001
P3 < 0.001
interventricular septal thickness, PWT= posterior wall thickness,
vs GIII (CAF vs control).
Table 3 Brachial ﬂow-mediated dilatation and hs-CRP in study groups.
GI (PAF) (n= 20) GII (CAF) (n= 22) GIII (control) (n= 20) P value
BBD (LS) (mm) 4.48 ± 0.53 4.50 ± 0.53 4.40 ± 0.55 P1 = 0.901
P2 = 0.663
P3 = 0.571
Brachial FMD diﬀerence (mm) 0.09 ± 0.05 0.09 ± 0.04 0.79 ± 0.07 P1 = 0.860
P2 < 0.001
P3 < 0.001
Percent change of FMD (LS) 1.96 ± 0.98 1.99 ± 0.89 18.3 ± 3.26 P1 = 0.919
P2 < 0.001
P3 < 0.001
Hs-CRP (mg/L) 8.35 ± 1.55 10.58 ± 1.75 3.61 ± 0.61 P1 < 0.001
P2 < 0.001
P3 < 0.001
BBD= brachial basal diameter; LS = longitudinal section; FMD= ﬂow-mediated dilatation; hs-CRP= high sensitive CRP.
P1: GI vs GII (paroxysmal vs chronic AF), P2: GI vs GIII (paroxysmal vs control), P3: GII vs GIII (chronic AF vs control).
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P< 0.05 was considered to be statistically signiﬁcant.
9. Results
Clinical characteristics and medications are reviewed in
Table 1.
In Table 2 there was a signiﬁcant increase of EDD when
compared patients with CAF with control group (P= 0.04).
Also, there was a signiﬁcant decrease of FS% when compared
either GI or GII with control group (P< 0.001 and
P= 0.003, respectively).
Left atrial diameter was signiﬁcantly increased when com-
pared either GI or GII with control group (P< 0.001). Also,
LAD signiﬁcantly increased when compared the patients with
CAF with the patients with PAF (P< 0.001).
In Table 3 brachial ﬂow-mediated dilatation difference and
percentage change of FMD were signiﬁcantly lower in groups I










Figure 1 Correlation between hs-CRP andsigniﬁcant difference in these parameters when compared the
patients with PAF and CAF.
High sensitive CRP was signiﬁcantly higher when com-
pared either group I or group II with the control group. Also
hs-CRP has signiﬁcantly increased when compared group II
with group I (P< 0.001). There was a negative correlation be-
tween high sensitive C-reactive protein and percent change of
FMD (Fig. 1).
10. Discussion
Atrial ﬁbrillation is associated with an increased thromboem-
bolic risk and prothrombotic state.13 Endothelial dysfunction
is a contributory factor to the prothrombotic state seen in
many cardiovascular disorders: including AF.13,14 Indeed,
endothelial dysfunction has been identiﬁed in many disease
states and has been associated with worse outcomes and car-




percent change of FMD in study group.
Figure 2 Longitudinal section of brachial artery before and after cuff inﬂation in patient.
Figure 4 Longitudinal section of brachial artery before and after cuff inﬂation in normal subject.
Figure 3 Longitudinal section of brachial artery before and after cuff inﬂation in patient with CAF.
The role of ﬂow-mediated dilatation and high sensitive C-reactive protein in paroxysmal atrial ﬁbrillation 215rosis, diabetes mellitus and many other conditions.14 While the
data in AF patients are more limited.
Brachial artery FMD is a validated, non-invasive tool to
quantify endothelial function. It has been very much used in
recent years, and there are numerous studies on FMD and car-
diovascular disease, vascular risk factors, or endothelial dys-
function therapy.15 In contrast, there are few studies on
FMD in atrial ﬁbrillation.
Our results show that the percentage change of FMD is sig-
niﬁcantly lower in patients with AF (paroxysmal or chronic) in
comparison to control subjects) (Figs. 2–4). These results sug-
gest that endothelial dysfunction and activation predominate
in the patients with AF which may be contributory to the
thrombotic state seen in these patients. Of note, FMD did
not differ signiﬁcantly among the subgroups of AF patient,
indicating that endothelial dysfunction exists whether the AF
is paroxysmal or permanent. These results are similar to the re-
sults of Freestone et al.16 who found endothelial dysfunction in
both paroxysmal and chronic AF.However, Freestone et al.16 evaluated the plasma level of
vWF as an index of endothelial dysfunction, which is affected
by many known cardiovascular risk factors. It is frequently ar-
gued that abnormalities in markers of endothelial function in
AF patients could be due to some known cardiovascular risks
that often coexist with AF. For example, elevated plasma level
of vWF is associated with established cardiovascular risk fac-
tors such as age,17 smoking,18 diabetes mellitus,19 choles-
terol,20 and hypertension.21 Although serum levels of vWF in
AF patients were compared to control in this study, control
subjects had few or no cardiovascular risk factors and this
may inﬂuence the serum level of vWF.
The study conducted by Matsue et al.22 suggested that pa-
tients with paroxysmal AF, even outside the AF period, are
comparable in the degree of endothelial dysfunction (measured
by digital reactive hyperemia pulse amplitude tonometry) to
persistent AF patients. This impairment of endothelial func-
tion is caused by the presence of paroxysmal AF itself, inde-
pendent of other coexisting comorbidities.
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tigated the relationship between inﬂammation (using known
serum or plasma vascular inﬂammatory markers) and AF,23
hs-CRP has evolved as the most robust and reproducible mar-
ker of vascular inﬂammation.24
Our study shows that the level of hs-CRP was higher
among patients with AF compared with control in sinus
rhythm. Also, persistent AF patients have higher hs-CRP lev-
els than paroxysmal AF patients and both have higher levels
than control suggesting that CRP may be a marker for inﬂam-
matory states that may promote the persistence of AF, poten-
tially by inducing structural and/or electrical remodeling of the
atria. These pathways may represent a novel mechanism by
which structural changes resulting from inﬂammation perpetu-
ate AF.
The precise, mechanism for the increased circulating hs-
CRP in AF is uncertain but might reﬂect active participation
of CRP in the local inﬂammatory response within the atrial
myocardium.23
In AF, inﬂammation might not only result in endothelial
damage, dysfunction or activation but also be linked directly
to thrombogenesis.25
Our results are similar to numerous studies who had re-
ported speciﬁcally on the association of CRP with the develop-
ment and maintenance of AF.26–29
Currently, it remains unclear whether inﬂammation is a
cause of AF or merely a consequence. Sata et al.30 attempted
to establish causality between inﬂammation and onset of AF
in 15 patients with paroxysmal AF. The study provided an in-
sight into the role of inﬂammatory process in AF and sug-
gested that inﬂammation might be an independent risk factor
for AF.11. Conclusions
The ﬁndings of our study suggested that the patients with PAF
are comparable in the degree of endothelial dysfunction to
CAF patients. This may explain why the risk of thromboem-
bolism in PAF is comparable with that in CAF patients. Also,
our study suggested that CRP may be a marker for inﬂamma-
tory states in AF patients that may promote the persistence of
AF. These ﬁndings require further testing and conﬁrmation in
a larger trial. Nevertheless, these pathways may provide a po-
tential target for pharmacological approaches for treating AF.
Randomized trials of agents such as anti-inﬂammatory and/or
other CRP lowering drugs may be warranted.References
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